01—Abstract
Summary
Summary of the 8-K filed February 26, 2026. Cited figures are marked; the original filing is the authoritative source.
Elevance Health (ELV) filed an 8-K on February 26, 2026, disclosing two items: a management reshuffle and a reaffirmation of full-year 2026 guidance.
Chief Financial Officer Mark Kaye will expand his remit to oversee Carelon, the company's healthcare services arm (pharmacy services, behavioral health, value-based care, and care delivery). Felicia Norwood, currently EVP and Chief Health Benefits Officer, will consolidate the company's major Health Benefits businesses under a single accountable structure spanning Commercial and Government. Peter D.
Haytaian, President of Carelon, will step down effective May 4, 2026, citing family commitments, and will serve as Special Advisor through December 31, 2026. The company states the departure is not related to any disagreement on operations, policies, or practices, and that Carelon's operating priorities and client commitments are unchanged. The guidance reaffirmation is the financially material element for investors.
Elevance reiterated 2026 GAAP shareholders' earnings of at least $22.30a per diluted share, which includes approximately $3.20 per diluted share of net unfavorable items. Excluding these items, adjusted shareholders' earnings are expected to be at least $25.50 per diluted share. The benefit expense ratio outlook of 90.2% plus or minus 50 basis points was also reaffirmed.
Because the company chose to reaffirm rather than revise guidance, the filing signals management confidence in the existing outlook, though the filing does not itemize the nature of the $3.20b in unfavorable items. The structural changes point toward tighter integration and executive accountability: a single leader for Health Benefits and a CFO with broader operational scope over Carelon. Investors should monitor whether the consolidation delivers the stated efficiency and coordination gains, whether Carelon's leadership transition proceeds without disruption to client relationships, and whether the company's guidance holds through the rest of 2026 given the sizable unfavorable items embedded in the outlook.
02—Key points
Key Highlights
- Management restructuring: CFO Mark Kaye expands oversight to include Carelon, while Felicia Norwood assumes consolidated leadership of the Health Benefits organization.
- Carelon leadership transition: Peter D. Haytaian steps down as EVP and President of Carelon effective May 4, 2026, and serves as Special Advisor through December 31, 2026.
- No disagreement cited: The company states Haytaian's departure is unrelated to any disagreement on operations, policies, or practices.
- 2026 GAAP EPS guidance reaffirmed: Shareholders' earnings expected to be at least $22.30 per diluted share.
- Adjusted EPS guidance reaffirmed: Excluding approximately $3.20 per diluted share of net unfavorable items, adjusted earnings are expected to be at least $25.50 per diluted share.
- Benefit expense ratio reaffirmed: Full-year 2026 guidance of 90.2% plus or minus 50 basis points.
- Strategic intent: Management positions Carelon as central to its strategy to lower the cost of care, with operating priorities and client commitments described as unchanged.
03—Questions
Frequently Asked Questions
Why is Peter Haytaian leaving Carelon?
The company says Haytaian is transitioning out of his role as EVP and President of Carelon effective May 4, 2026, to devote more time to family commitments. He will remain with the company as Special Advisor through December 31, 2026, to support continuity. The company states the decision is not the result of any disagreement on operations, policies, or practices.
Who will lead Carelon after the transition?
Mark Kaye, Executive Vice President and Chief Financial Officer, will expand his responsibilities to include oversight of Carelon, which covers pharmacy services, behavioral health, value-based care, and care delivery. The filing does not name a separate dedicated Carelon president.
What does the consolidated Health Benefits organization mean for investors?
Felicia Norwood will lead a single accountable structure bringing together the company's major Health Benefits businesses and core operating functions across Commercial and Government. Management says this improves coordination, product, operations, and growth alignment. The filing does not quantify any expected cost savings or financial impact.
Did Elevance change its 2026 financial guidance?
No. Elevance reaffirmed its 2026 guidance: GAAP shareholders' earnings of at least $22.30 per diluted share, adjusted earnings of at least $25.50 per diluted share excluding about $3.20 in net unfavorable items, and a benefit expense ratio of 90.2% plus or minus 50 basis points.
What are the approximately $3.20 per diluted share of net unfavorable items?
The filing does not itemize the $3.20 per diluted share of net unfavorable items. Investors seeking the composition of these items should review the company's earnings materials or subsequent SEC filings.
04—Continue